PMID- 29505699
OWN - NLM
STAT- MEDLINE
DCOM- 20190816
LR  - 20240328
IS  - 1615-9861 (Electronic)
IS  - 1615-9853 (Print)
IS  - 1615-9853 (Linking)
VI  - 18
IP  - 12
DP  - 2018 Jun
TI  - Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and 
      Personalized Target Selection.
PG  - e1700284
LID - 10.1002/pmic.201700284 [doi]
LID - 1700284
AB  - Immunotherapy is revolutionizing cancer treatment and has shown success in 
      particular for tumors with a high mutational load. These effects have been linked 
      to neoantigens derived from patient-specific mutations. To expand efficacious 
      immunotherapy approaches to the vast majority of tumor types and patient 
      populations carrying only a few mutations and maybe not a single presented 
      neoepitope, it is necessary to expand the target space to non-mutated 
      cancer-associated antigens. Mass spectrometry enables the direct and unbiased 
      discovery and selection of tumor-specific human leukocyte antigen (HLA) peptides 
      that can be used to define targets for immunotherapy. Combining these targets 
      into a warehouse allows for multi-target therapy and accelerated clinical 
      application. For precise personalization aimed at optimally ensuring treatment 
      efficacy and safety, it is necessary to assess the presence of the target on each 
      individual patient's tumor. Here we show how LC-MS paired with gene expression 
      data was used to define mRNA biomarkers currently being used as diagnostic test 
      IMADETECT for patient inclusion and personalized target selection within two 
      clinical trials (NCT02876510, NCT03247309). Thus, we present a way how to 
      translate HLA peptide presentation into gene expression thresholds for companion 
      diagnostics in immunotherapy considering the peptide-specific correlation to its 
      encoding mRNA.
CI  - (c) 2018 The Authors. Proteomics Published by WILEY-VCH Verlag GmbH & Co. KGaA, 
      Weinheim.
FAU - Fritsche, Jens
AU  - Fritsche J
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Rakitsch, Barbara
AU  - Rakitsch B
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Hoffgaard, Franziska
AU  - Hoffgaard F
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Romer, Michael
AU  - Romer M
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Schuster, Heiko
AU  - Schuster H
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Kowalewski, Daniel J
AU  - Kowalewski DJ
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Priemer, Martin
AU  - Priemer M
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Stos-Zweifel, Vlatka
AU  - Stos-Zweifel V
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Horzer, Helen
AU  - Horzer H
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Satelli, Arun
AU  - Satelli A
AD  - Immatics US, Houston, Texas.
FAU - Sonntag, Annika
AU  - Sonntag A
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Goldfinger, Valentina
AU  - Goldfinger V
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Song, Colette
AU  - Song C
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Mahr, Andrea
AU  - Mahr A
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Ott, Martina
AU  - Ott M
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Schoor, Oliver
AU  - Schoor O
AD  - Immatics Biotechnologies, Tubingen, Germany.
FAU - Weinschenk, Toni
AU  - Weinschenk T
AD  - Immatics Biotechnologies, Tubingen, Germany.
AD  - Immatics US, Houston, Texas.
LA  - eng
SI  - ClinicalTrials.gov/NCT02876510
SI  - ClinicalTrials.gov/NCT03247309
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180410
PL  - Germany
TA  - Proteomics
JT  - Proteomics
JID - 101092707
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes)
RN  - 0 (HLA Antigens)
RN  - 0 (Peptide Fragments)
RN  - 0 (RNA, Messenger)
MH  - Antigen Presentation/immunology
MH  - Antigens, Neoplasm/analysis/immunology/*metabolism
MH  - Decision Making
MH  - Epitopes/immunology/metabolism
MH  - HLA Antigens/analysis/immunology/*metabolism
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - *Immunotherapy
MH  - Mass Spectrometry/methods
MH  - Neoplasms/immunology/*metabolism
MH  - Peptide Fragments/analysis/immunology/*metabolism
MH  - *Precision Medicine
MH  - Proteogenomics/*methods
MH  - RNA, Messenger/analysis/genetics/immunology
PMC - PMC6032917
OTO - NOTNLM
OT  - Human leukocyte antigen
OT  - Immunopeptidome
OT  - Immunotherapy
OT  - Label-free quantitation
OT  - Precision medicine
EDAT- 2018/03/06 06:00
MHDA- 2019/08/17 06:00
PMCR- 2018/07/05
CRDT- 2018/03/06 06:00
PHST- 2017/11/21 00:00 [received]
PHST- 2018/02/15 00:00 [revised]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2019/08/17 06:00 [medline]
PHST- 2018/03/06 06:00 [entrez]
PHST- 2018/07/05 00:00 [pmc-release]
AID - PMIC12846 [pii]
AID - 10.1002/pmic.201700284 [doi]
PST - ppublish
SO  - Proteomics. 2018 Jun;18(12):e1700284. doi: 10.1002/pmic.201700284. Epub 2018 Apr 
      10.